Skip to main content
Joan Shen, MD, Obstetrics & Gynecology, Winston Salem, NC

JoanShenMD

Obstetrics & Gynecology Winston Salem, NC

General Gynecology

Physician

Dr. Shen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shen's full profile

Already have an account?

  • Office

    250 Charlois Blvd
    Winston Salem, NC 27103
    Phone+1 336-718-1000
    Fax+1 336-718-1052

Education & Training

  • West Virginia University
    West Virginia UniversityResidency, Obstetrics and Gynecology, 1984 - 1988
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1984

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2003 - 2020
  • WA State Medical License
    WA State Medical License 1991 - 2017
  • NV State Medical License
    NV State Medical License 2002 - 2005
  • PA State Medical License
    PA State Medical License 2002 - 2004

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Press Mentions

  • I-mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
    I-mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in ChinaDecember 15th, 2021
  • I-mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
    I-mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021December 14th, 2021
  • I Mab : Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors - Form 6-K
    I Mab : Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors - Form 6-KDecember 6th, 2021
  • Join now to see all

Professional Memberships